Abstract #0287
3D MR Spectroscopic Imaging of 2-Hydroxyglutarate in patients with mutant IDH1 glioma
Ovidiu Cristian Andronesi 1 , Franziska Loebel 2 , Wolfgang Bogner 3 , Malgorzata Marjanska 4 , Elizabeth Gerstner 5 , Andrew Chi 5 , Tracy T. Batchelor 5 , Daniel P. Cahill 6 , and Bruce R. Rosen 1
1
Martinos Center for Biomedical Imaging,
Department of Radiology, Massachusetts General Hospital,
Harvard Medical School, Boston, MA, United States,
2
Department
of Neurosurgery, Massachusetts General Hospital, Boston,
MA, United States,
3
MR
Center of Excellence, Department of Radiology, Medical
University Vienna, Vienna, Vienna, Austria,
4
Center
for Magnetic Resonance Research, University of
Minnesota, MN, United States,
5
Pappas
Center of Neuro-Oncology, Department of Neurology,
Massachusetts General Hospital, Harvard Medical School,
Boston, MA, United States,
6
Department
of Neurosurgery, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
High levels of 2-hydroxyglutarate (2HG) represent the
hallmark metabolic alteration in mutant IDH gliomas. 2HG
has been proposed as an ideal biomarker to diagnose and
monitor treatment response of mutant IDH gliomas. We
show here newly that 3D MR spectroscopic imaging (MRSI)
of 2HG is feasible clinically in glioma patients. A
novel 3D MRSI sequence was designed to edit reliably and
efficiently the 2HG levels. Results obtained serially in
mutant IDH glioma patients are shown.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
